Giuseppe Leone: This Review by Offidani’s Group Compares Clinical Trials and Outlines Prospects
LABORATORY Professionals International reposted Giuseppe Leone’s post on LinkedIn:
“At major international conferences in 2024, important data emerged on new approaches capable of improving outcomes even in high-risk or very advanced disease. Upfront quadruplet combinations, including anti-CD38 monoclonal antibodies, have proven to be the best therapy in terms of depth of response and long-term efficacy in both transplant-eligible and ineligible patients. Despite the introduction of these therapies, high-risk multiple myeloma (MM) remains challenging to treat. This review by Offidani’s group compares clinical trials and outlines prospects.”
Title: Guest Edtor: Pellegrino Musto NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES
Authors: Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Antonella Poloni, Massimo Offidani
Read more here.
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda